HRP20192218T1 - Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene - Google Patents
Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene Download PDFInfo
- Publication number
- HRP20192218T1 HRP20192218T1 HRP20192218TT HRP20192218T HRP20192218T1 HR P20192218 T1 HRP20192218 T1 HR P20192218T1 HR P20192218T T HRP20192218T T HR P20192218TT HR P20192218 T HRP20192218 T HR P20192218T HR P20192218 T1 HRP20192218 T1 HR P20192218T1
- Authority
- HR
- Croatia
- Prior art keywords
- human
- gene
- segments
- mouse
- light chain
- Prior art date
Links
- 238000011577 humanized mouse model Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 38
- 241001529936 Murinae Species 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 7
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108090000143 Mouse Proteins Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24046—Adamalysin (3.4.24.46)
Claims (14)
1. Miš čiji genom sadrži:
(a) umetanje jednog ili više humanih segmenata gena VL i jednog ili više humanih segmenata gena JL iznad gena konstantne regije mišjeg imunoglobulinskog lakog lanca, naznačeno time, što su jedan ili više humanih segmenata gena VL i jedan ili više humanih segmenata gena JL operativno povezani s genom konstantne regije mišjeg imunoglobulinskog lakog lanca;
(b) umetanje jednog ili više humanih segmenata gena VL i jednog ili više humanih segmenata gena JL iznad gena konstantne regije mišjeg imunoglobulinskog teškog lanca, naznačeno time, što su jedan ili više humanih segmenata gena VL i jedan ili više humanih segmenata gena JL operativno povezani s genom konstantne regije mišjeg imunoglobulinskog teškog lanca; i
(c) ektopijsku sekvencu nukleinske kiseline koja šifrira mišji protein ADAM6a ili njegov funkcionalni fragment i ektopijsku sekvencu nukleinske kiseline koja šifrira mišji protein ADAM6b ili njegov funkcionalni fragment, naznačeno time, što se mišji proteini ADAM6a i ADAM6b ili njihovi funkcionalni fragmenti izražavaju iz ektopijskih sekvenci nukleinske kiseline,
naznačen time, što miš izražava antitijelo koje sadrži (i) polipeptid koji sadrži varijabilnu domenu humanog lakog lanca povezanu s konstantnom domenom mišjeg teškog lanca; i (ii) polipeptid koji sadrži varijabilnu domenu humanog lakog lanca povezanu s konstantnom domenom mišjeg lakog lanca.
2. Miš prema patentnom zahtjevu 1, naznačen time, što je gen konstantne regije mišjeg imunoglobulinskog lakog lanca mišji Cκ.
3. Miš prema patentnom zahtjevu 1 ili 2, naznačen time, što jedan ili više humanih segmenata gena VL i jedan ili više humanih segmenata gena JL iznad gena konstantne regije mišjeg imunoglobulinskog lakog lanca jesu jedan ili više humanih segmenata gena Vκ i jedan ili više humanih segmenata gena Jκ.
4. Miš prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što jedan ili više humanih segmenata gena VL i jedan ili više humanih segmenata gena JL iznad gena konstantne regije mišjeg imunoglobulinskog teškog lanca jesu jedan ili više humanih segmenata gena Vκ i jedan ili više humanih segmenata gena Jκ.
5. Miš prema bilo kojem patentnom zahtjevu od 1 do 4, naznačen time, što su ektopijske sekvence nukleinske kiseline prisutne između dva od umetnutog jednog ili više humanih segmenata gena VL i jednog ili više humanih segmenata gena JL navedenih u (b).
6. Miš prema patentnom zahtjevu 5, naznačen time, što umetnuti jedan ili više humanih segmenata gena VL i jedan ili više humanih segment gena JL jesu humani segmenti gena lakog lanca κ ili humani segmenti gena lakog lanca λ.
7. Miš prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što umetnuti jedan ili više humanih segmenata gena VL uključuje Vκ5-2 i Vκ4-1, a ektopijske sekvence nukleinske kiseline koje šifriraju mišje proteine ADAM6a i ADAM6b ili njihove funkcionalne fragmente su prisutne između Vκ5-2 i Vκ4-1.
8. Miš prema bilo kojem patentnom zahtjevu od 1 do 6, naznačen time, što umetnuti jedan ili više humanih segmenata gena VL uključuje Vκ4-1 i umetnuti jedan ili više humanih segmenata gena JL uključuje Jκ1, a ektopijske sekvence nukleinske kiseline koje šifriraju mišje proteine ADAM6a i ADAM6b ili njihove funkcionalne fragmente su prisutne između Vκ4-1 i Jκ1.
9. Miš prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što miš sadrži jedan ili više endogenih segmenata gena VL i/ili jedan ili više endogenih segmenata gena JL koji nisu sposobni za vršenje preuređenja kako bi formirali varijabilnu sekvencu imunoglobulinskog lakog lanca u mišu.
10. Miš prema bilo kojem od prethodnih zahtjeva, naznačen time, što miš sadrži deleciju ili zamjenu jedne ili više endogenih sekvenci gena imunoglobulinskog teškog lanca.
11. Stanica dobivena iz miša prema patentnom zahtjevu 1.
12. Stanica prema patentnom zahtjevu 11, naznačena time, što stanica jest B stanica.
13. Hibridom dobiven iz B stanice prema patentnom zahtjevu 12.
14. Metoda za dobivanje antitijela koje se vezuje za interesni antigen, naznačena time, što se sastoji od
(a) izlaganja miša iz patentnog zahtjeva 1 interesnom antigenu;
(b) izoliranja jedne ili više B stanica miša, naznačeno time, što jedna ili više B stanica izražavaju antitijelo koje se vezuje za interesni antigen;
(c) identifikacije sekvence nukleinske kiseline koja šifrira jednu od varijabilnih domena lakog lanca antitijela koje se vezuje za dani interesni antigen, naznačeno time, što antitijelo sadrži varijabilnu domenu humanog imunoglobulinskog lakog lanca κ povezanu s konstantnom domenom mišjeg lakog lanca i varijabilnu domenu humanog imunoglobulinskog lakog lanca κ povezanu s konstantnom domenom mišjeg teškog lanca; i
(d) primjene sekvence nukleinske kiseline iz (c) sa sekvencom nukleinske kiseline konstantne regije humanog imunoglobulina radi dobivanja humanog antitijela koje se vezuje za interesni antigen.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593463P | 2012-02-01 | 2012-02-01 | |
| US201261677538P | 2012-07-31 | 2012-07-31 | |
| EP13704329.5A EP2809150B1 (en) | 2012-02-01 | 2013-02-01 | Humanized mice that express heavy chains containing vl domains |
| PCT/US2013/024295 WO2013116609A1 (en) | 2012-02-01 | 2013-02-01 | Humanized rodents that express heavy chains containing vl domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192218T1 true HRP20192218T1 (hr) | 2020-03-06 |
Family
ID=47714588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192218TT HRP20192218T1 (hr) | 2012-02-01 | 2019-12-10 | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene |
| HRP20210987TT HRP20210987T1 (hr) | 2012-02-01 | 2021-06-23 | Humanizirani glodavci koji eksprimiraju teške lance koji sadrže vl domene |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210987TT HRP20210987T1 (hr) | 2012-02-01 | 2021-06-23 | Humanizirani glodavci koji eksprimiraju teške lance koji sadrže vl domene |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20130212719A1 (hr) |
| EP (3) | EP3912465A1 (hr) |
| JP (6) | JP2015505477A (hr) |
| KR (2) | KR20140123983A (hr) |
| CN (2) | CN106117364B (hr) |
| AU (3) | AU2013204758B2 (hr) |
| BR (1) | BR112014018843B1 (hr) |
| CA (1) | CA2863175A1 (hr) |
| CY (2) | CY1122419T1 (hr) |
| DK (2) | DK2809150T3 (hr) |
| ES (2) | ES2753774T3 (hr) |
| HK (1) | HK1202771A1 (hr) |
| HR (2) | HRP20192218T1 (hr) |
| HU (2) | HUE055610T2 (hr) |
| IL (3) | IL233827A0 (hr) |
| LT (2) | LT2809150T (hr) |
| ME (1) | ME03611B (hr) |
| MX (2) | MX2020003491A (hr) |
| NZ (3) | NZ627977A (hr) |
| PL (2) | PL2809150T3 (hr) |
| PT (2) | PT3597038T (hr) |
| RS (2) | RS59699B1 (hr) |
| RU (2) | RU2664185C2 (hr) |
| SG (3) | SG10201913428QA (hr) |
| SI (2) | SI2809150T1 (hr) |
| WO (1) | WO2013116609A1 (hr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2436044T3 (es) * | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| ES2965212T3 (es) | 2009-07-08 | 2024-04-11 | Kymab Ltd | Modelos de animales y moléculas terapéuticas |
| NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| CA2846322A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| MX356429B (es) | 2011-12-20 | 2018-05-29 | Regeneron Pharma | Ratones con cadena ligera humanizada. |
| DK2809150T3 (da) * | 2012-02-01 | 2019-12-09 | Regeneron Pharma | Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| LT3597037T (lt) | 2012-06-12 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| JP7133902B2 (ja) | 2013-10-01 | 2022-09-09 | カイマブ・リミテッド | 動物モデル及び治療用分子 |
| JP2017510273A (ja) | 2014-03-21 | 2017-04-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 異なる結合特性を示すｖｌ抗原結合タンパク質 |
| KR20210088756A (ko) | 2014-03-21 | 2021-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| AU2016232715A1 (en) * | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| ES2959608T3 (es) * | 2015-04-03 | 2024-02-27 | Dana Farber Cancer Inst Inc | Composición y métodos de edición del genoma de células B |
| KR20240016444A (ko) | 2016-05-20 | 2024-02-06 | 리제너론 파마슈티칼스 인코포레이티드 | 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법 |
| CN110719732B (zh) * | 2017-03-30 | 2022-11-18 | 犹他州立大学 | 表达蜘蛛丝的转基因蚕 |
| HUE060608T2 (hu) * | 2017-12-05 | 2023-03-28 | Regeneron Pharma | Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása |
| RU2020131383A (ru) * | 2018-03-24 | 2022-04-26 | Ридженерон Фармасьютикалз, Инк. | Генетически модифицированные животные, отличные от человека, для выработки терапевтических антител против комплексов пептид-mhc, способы их получения и варианты применения |
| SG11202012084WA (en) * | 2018-06-14 | 2021-01-28 | Regeneron Pharma | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
| US20220090060A1 (en) | 2020-09-11 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| EP4262373A1 (en) | 2020-12-16 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
| CN114196626A (zh) * | 2022-02-16 | 2022-03-18 | 北京国卫生物科技有限公司 | 脐带间充质干细胞及其分离培养扩增方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| CA2634294A1 (en) * | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN101016543A (zh) * | 2000-11-17 | 2007-08-15 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法 |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| WO2003081993A2 (en) * | 2002-03-22 | 2003-10-09 | Origen Therapeutics | Transgenic aves producing human polyclonal antibodies |
| MXPA06000562A (es) * | 2003-07-15 | 2006-03-30 | Therapeutic Human Polyclonals | Loci de inmunoglobulina humanizada. |
| WO2006044962A1 (en) | 2004-10-19 | 2006-04-27 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| US20080184380A1 (en) * | 2004-10-22 | 2008-07-31 | Therapeutic Human Polyclonals Inc. | Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals |
| JP5514539B2 (ja) * | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
| EP2064325B1 (en) * | 2006-09-01 | 2011-12-07 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| WO2009026660A1 (en) * | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| SG10201605394SA (en) * | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| ES2436044T3 (es) * | 2008-05-23 | 2013-12-26 | Ablexis, Llc | Procedimiento de generación de anticuerpos de dominio VL individual en animales transgénicos |
| EP2556747B1 (en) * | 2008-06-27 | 2020-12-02 | Merus N.V. | Antibody producing transgenic mice |
| BRPI0917352A2 (pt) * | 2008-08-29 | 2017-08-22 | Symphogen As | Métodos para produção de uma biblioteca de pares cognatos que compreende sequências ligadas que codificam regiões variáveis e para gerar um vetor que codifica um anticorpo quimérico com regiões de seres humanos constantes e regiões variáveis não humanas, biblioteca de vetores, e método para produção de uma biblioteca de sequências de imunoglobulina derivadas de aves |
| US9085795B2 (en) * | 2009-02-04 | 2015-07-21 | Molecular Innovations, Inc. | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies |
| US20120204278A1 (en) * | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| ES2965212T3 (es) * | 2009-07-08 | 2024-04-11 | Kymab Ltd | Modelos de animales y moléculas terapéuticas |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP2582230A1 (en) * | 2010-06-17 | 2013-04-24 | Kymab Limited | Animal models and therapeutic molecules |
| NZ707327A (en) * | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| DK2550363T3 (en) * | 2011-02-25 | 2015-03-23 | Regeneron Pharma | ADAM6 mice |
| ES2872081T3 (es) * | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| MX356429B (es) * | 2011-12-20 | 2018-05-29 | Regeneron Pharma | Ratones con cadena ligera humanizada. |
| DK2809150T3 (da) * | 2012-02-01 | 2019-12-09 | Regeneron Pharma | Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner |
| LT3597037T (lt) * | 2012-06-12 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu |
| LT3407709T (lt) * | 2016-11-04 | 2020-10-12 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys sukonstruotą imunoglobulino lambda lengvosios grandinės lokusą |
-
2013
- 2013-02-01 DK DK13704329T patent/DK2809150T3/da active
- 2013-02-01 PL PL13704329T patent/PL2809150T3/pl unknown
- 2013-02-01 DK DK19191081.9T patent/DK3597038T3/da active
- 2013-02-01 RU RU2014133653A patent/RU2664185C2/ru active
- 2013-02-01 ES ES13704329T patent/ES2753774T3/es active Active
- 2013-02-01 WO PCT/US2013/024295 patent/WO2013116609A1/en active Application Filing
- 2013-02-01 CN CN201610371631.3A patent/CN106117364B/zh active Active
- 2013-02-01 JP JP2014555736A patent/JP2015505477A/ja not_active Withdrawn
- 2013-02-01 NZ NZ627977A patent/NZ627977A/en active IP Right Revival
- 2013-02-01 MX MX2020003491A patent/MX2020003491A/es unknown
- 2013-02-01 CN CN201380017544.2A patent/CN104202971B/zh active Active
- 2013-02-01 RU RU2018122695A patent/RU2770016C2/ru active
- 2013-02-01 SI SI201331592T patent/SI2809150T1/sl unknown
- 2013-02-01 EP EP21167681.2A patent/EP3912465A1/en active Pending
- 2013-02-01 EP EP13704329.5A patent/EP2809150B1/en active Active
- 2013-02-01 SG SG10201913428QA patent/SG10201913428QA/en unknown
- 2013-02-01 SG SG10201606256TA patent/SG10201606256TA/en unknown
- 2013-02-01 HU HUE19191081A patent/HUE055610T2/hu unknown
- 2013-02-01 AU AU2013204758A patent/AU2013204758B2/en active Active
- 2013-02-01 EP EP19191081.9A patent/EP3597038B1/en active Active
- 2013-02-01 ME MEP-2019-348A patent/ME03611B/me unknown
- 2013-02-01 RS RS20191615A patent/RS59699B1/sr unknown
- 2013-02-01 RS RS20210791A patent/RS62023B1/sr unknown
- 2013-02-01 US US13/756,889 patent/US20130212719A1/en not_active Abandoned
- 2013-02-01 HU HUE13704329A patent/HUE046744T2/hu unknown
- 2013-02-01 PT PT191910819T patent/PT3597038T/pt unknown
- 2013-02-01 NZ NZ734504A patent/NZ734504A/en unknown
- 2013-02-01 PT PT137043295T patent/PT2809150T/pt unknown
- 2013-02-01 NZ NZ719228A patent/NZ719228A/en unknown
- 2013-02-01 LT LT13704329T patent/LT2809150T/lt unknown
- 2013-02-01 LT LTEP19191081.9T patent/LT3597038T/lt unknown
- 2013-02-01 KR KR1020147024417A patent/KR20140123983A/ko not_active Application Discontinuation
- 2013-02-01 BR BR112014018843-2A patent/BR112014018843B1/pt active IP Right Grant
- 2013-02-01 SG SG11201404477YA patent/SG11201404477YA/en unknown
- 2013-02-01 SI SI201331882T patent/SI3597038T1/sl unknown
- 2013-02-01 ES ES19191081T patent/ES2870703T3/es active Active
- 2013-02-01 KR KR1020187037872A patent/KR20190006029A/ko not_active Application Discontinuation
- 2013-02-01 PL PL19191081T patent/PL3597038T3/pl unknown
- 2013-02-01 CA CA2863175A patent/CA2863175A1/en active Pending
-
2014
- 2014-07-27 IL IL233827A patent/IL233827A0/en active IP Right Grant
- 2014-07-31 MX MX2019002517A patent/MX2019002517A/es active IP Right Grant
-
2015
- 2015-04-10 HK HK15103518.0A patent/HK1202771A1/xx unknown
- 2015-10-23 AU AU2015246154A patent/AU2015246154B2/en active Active
-
2016
- 2016-10-14 US US15/294,488 patent/US20170094955A1/en not_active Abandoned
-
2017
- 2017-10-27 AU AU2017251848A patent/AU2017251848B2/en active Active
-
2018
- 2018-02-09 JP JP2018022012A patent/JP6698718B2/ja active Active
- 2018-08-21 IL IL261280A patent/IL261280B/en active IP Right Grant
-
2019
- 2019-07-12 JP JP2019130027A patent/JP6942757B2/ja active Active
- 2019-08-13 IL IL268675A patent/IL268675B/en active IP Right Grant
- 2019-12-10 CY CY20191101302T patent/CY1122419T1/el unknown
- 2019-12-10 HR HRP20192218TT patent/HRP20192218T1/hr unknown
-
2021
- 2021-04-07 US US17/224,524 patent/US20210368751A1/en active Pending
- 2021-06-15 JP JP2021099420A patent/JP7187615B2/ja active Active
- 2021-06-23 HR HRP20210987TT patent/HRP20210987T1/hr unknown
- 2021-07-20 CY CY20211100659T patent/CY1124361T1/el unknown
-
2022
- 2022-11-30 JP JP2022191963A patent/JP2023014242A/ja active Pending
-
2023
- 2023-10-05 JP JP2023173593A patent/JP2023168590A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
| HRP20210916T1 (hr) | Miševi s ljudskim univerzalnim lakim lancem | |
| HRP20190897T1 (hr) | Laki lanac humaniziranih miševa | |
| JP2021137030A5 (hr) | ||
| HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa | |
| HRP20191333T1 (hr) | Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost | |
| JP2015505477A5 (hr) | ||
| HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
| HRP20190807T1 (hr) | Miševi koji izražavaju imunoglobulinski hibridni laki lanac s humanom varijabilnom regijom | |
| HRP20201634T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 | |
| HRP20191680T1 (hr) | Neljudske životinje koje izražavaju antitijela sa zajedničkim lakim lancem | |
| JP2015502177A5 (hr) | ||
| JP2014110814A5 (hr) | ||
| NZ711451A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| HRP20171193T1 (hr) | Proizvodnja vezivnih molekula | |
| HRP20190706T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| WO2012145469A8 (en) | Human monoclonal antibodies specific for glypican-3 and use thereof | |
| HRP20192311T4 (hr) | Adam6 miševi | |
| JP2014524243A5 (hr) | ||
| JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
| HRP20220081T1 (hr) | Bcma i cd3 bispecifična t stanica koja uključuje konstrukte protutijela | |
| BR112016021572A2 (pt) | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação | |
| MX2015012540A (es) | Ratón de cadena ligera común. | |
| RU2021129958A (ru) | Отличные от человека животные со сконструированным локусом легкой лямбда-цепи иммуноглобулина | |
| RU2019121863A (ru) | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |